1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Community Acquired Pneumonia-Pipeline Insights, 2016

Community Acquired Pneumonia-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Community Acquired Pneumonia-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Community Acquired Pneumonia. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Community Acquired Pneumonia. DelveInsight’s Report also assesses the Community Acquired Pneumonia therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Community Acquired Pneumonia
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Community Acquired Pneumonia pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Community Acquired Pneumonia and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Community Acquired Pneumonia-Pipeline Insights, 2016

Illustrative Table of contents

- Community Acquired Pneumonia Overview
- Community Acquired Pneumonia Pipeline Therapeutics
- Community Acquired Pneumonia Therapeutics under Development by Companies
- Community Acquired Pneumonia Filed and Phase III Products
- Comparative Analysis
- Community Acquired Pneumonia Phase II Products
- Comparative Analysis
- Community Acquired Pneumonia Phase I and IND Filed Products
- Comparative Analysis
- Community Acquired Pneumonia Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Community Acquired Pneumonia - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Community Acquired Pneumonia - Discontinued Products
- Community Acquired Pneumonia - Dormant Products
- Companies Involved in Therapeutics Development for Community Acquired Pneumonia
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Community Acquired Pneumonia, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Community Acquired Pneumonia Assessment by Monotherapy Products
- Community Acquired Pneumonia Assessment by Combination Products
- Community Acquired Pneumonia Assessment by Route of Administration
- Community Acquired Pneumonia Assessment by Stage and Route of Administration
- Community Acquired Pneumonia Assessment by Molecule Type
- Community Acquired Pneumonia Assessment by Stage and Molecule Type
- Community Acquired Pneumonia Therapeutics - Discontinued Products
- Community Acquired Pneumonia Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Community Acquired Pneumonia, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Community Acquired Pneumonia Assessment by Monotherapy Products
- Community Acquired Pneumonia Assessment by Combination Products
- Community Acquired Pneumonia Assessment by Route of Administration
- Community Acquired Pneumonia Assessment by Stage and Route of Administration
- Community Acquired Pneumonia Assessment by Molecule Type
- Community Acquired Pneumonia Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.